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INTRODUCTION
Chronic granulomatous disease (CGD) is a rare inherited primary immunodeficiency characterized by a compromised immune system due to impaired neutrophil function. CGD often leads to premature death triggered by severe and therapy-resistant infections. 1 The antimicrobial activity of phagocytic cells mainly depends on the production of reactive oxygen species (ROS) by the nicotinamide dinucleotide phosphate (NADPH) oxidase enzyme complex. This complex consists of two membrane spanning subunits, gp91 phox and p22 phox , as well as three cytosolic components p47 phox , p67 phox , p40 phox . In addition, the low-molecular-weight GTP-binding proteins Rac1 and Rac2 are also involved in the regulation of the NADPH oxidase activity. 2 CGD patients harboring genetic mutations in one of the subunits of the oxidase complex have a significantly reduced ROS production. 3 The X-linked form of the disease (X-CGD), which is caused by mutations in the X-linked gp91 phox gene (CYBB) accounts for the majority (65-85%) of CGD cases. [4] [5] [6] The only curative treatment currently available is hematopoietic stem cell transplantation. 7, 8 For those patients lacking a suitable donor, gene therapy of autologous hematopoietic stem cells (CD34   +   ) is a promising alternative, as demonstrated in pioneering phase I/II clinical trials (as reviewed elsewhere). 9 Despite the undisputed clinical benefit experienced by all X-CGD subjects treated by gene therapy, the vector-related genotoxic effects observed in some of the patients clearly emphasized the development of safety and efficacy improved vectors (reviewed in ref. 10 ). Consequently, novel retroviral vectors intended for clinical trials must be evaluated extensively for safety and efficacy. The predictive values of these assays depend on the test systems used. For X-CGD a gp91 phox deficient human myelomonocytic cell line (XCGD-PLB985), 11 is a valuable system for initial vector testing, however, it can only provide limited predictive data on clinical efficacy or safety. First, it is highly permissive for vector transduction in contrast to primary CD34 + HSCs and cannot give detailed insights in gp91 phox expression kinetic during myeloid differentiation, e.g. for the evaluation of promoter regulation or studies on basic biology. Next, disproportional ROS production was previously shown for XCGD-PLB985 cells transduced with a gammaretroviral vector most likely due to defects in intracellular trafficking and maturation processes described for the parental cell line HL-60. 12, 13 Furthermore, complete vector inactivation by epigenetic mechanisms was identified as one of the problems encountered in our Phase I/II clinical trial, a problem we never experienced in XCGD-PLB985 cells. 14, 15 Hence, the best test system to evaluate vectors for gene therapy of X-CGD are primary CD34 + cells lacking gp91 phox expression. However, for X-CGD, only minute amounts of patient derived primary material are available for research and thus, murine models of the disease are predominantly used for vector testing. 16 Besides the low incidence of the disease (1 in 120,000 to 1 in 250,000), 17, 18 ethical considerations limit the availability of X-CGD CD34 + cells. In an approach to overcome the acute paucity of primary human X-CGD cells, we developed a lentiviral vector for the stable knockdown of gp91 phox in human primary hematopoietic stem cells from healthy donors. Efficient knock down of endogenous gp91 phox Received 2 May 2014; accepted 26 June 2014 Innovative approaches for the treatment of rare inherited diseases are hampered by limited availability of patient derived samples for preclinical research. This also applies for the evaluation of novel vector systems for the gene therapy of monogenic hematological diseases like X-linked chronic granulomatous disease (X-CGD), a severe primary immunodeficiency caused by mutations in the gp91 phox subunit of the phagocytic NADPH oxidase. Since current gene therapy protocols involve ex vivo gene modification of autologous CD34
+ hematopoietic stem cells (HSC), the ideal preclinical model should simulate faithfully this procedure. However, the low availability of patient-derived CD34 + cells limits the feasibility of this approach. Here, we describe a straightforward experimental strategy that circumvents this limitation. The knock down of gp91 phox expression upon lentiviral delivery of shRNAs into CD34
+ cells from healthy donors generates sufficient amounts of X-CGD CD34 + cells which subsequently can be used for the evaluation of novel gene therapeutic strategies using a codon-optimized gp91 phox transgene. We have used this strategy to test the potential of a novel gene therapy vector for X-CGD. The first two authors contributed equally to this work. 1 was achieved in PLB985 cells and in primary human CD34 + cells as assessed by FACS and western blot and resulted in loss of NADPHoxidase activity closely matching the phenotype of X-CGD patient samples. These cells were used to test the efficacy of a novel lentiviral vector containing a codon-optimized version of gp91 phox . Hence, this approach represents a valuable system for testing viral vectors in human primary X-CGD cells as well as for research focusing on the basic biology of gp91 phox .
ReSUlTS
Screening for optimal shRNAs and vector design for efficient gp91 phox knock down Initially, we tested five shRNAs individually in the context of a lentiviral vector for their activity to knock down endogenous gp91 phox expression in the human myelomonocytic cell line PLB-985 (Figure 1a,b) . Knock down efficiency of gp91 phox expression was assessed in undifferentiated transduced cells and upon granulocytic differentiation by measuring gp91 phox protein at the cell surface of transduced cells by flow cytometry using the human monoclonal anti-gp91 phox antibody 7D5 19 ( Figure 1c ). Significant reduction of gp91 phox positive cells was achieved with two shRNAs, sh88 and sh91 (P < 0.001 and P = 0.002, respectively), which were subsequently combined in a single lentiviral vector under the control of two distinct human DNA polymerase III promoters, namely U6 and H1. The insertion of the H1-sh91 sequence into the viral 3′ long terminal repeat (LTR) results in two transcription units per provirus upon reverse transcription (Figure 1d ). This design led to the highest knock-down efficiency (88 ± 4%) in differentiated CD11b
+ PLB-985 cells as estimated from gp91 phox surface expression (Figure 1c ). Clonal populations harboring 1-2 vector integrants confirmed gp91 phox knock down at the mRNA level with a mean efficiency of 80 ± 12% (n = 9, Figure 1e ). In this final knock down (KD) vector (LV.sh88/91.Cer, Figure 1d phox coding region is shown aligned to the synthetic gp91s sequence. The best performers are highlighted in red. (c) PLB-985 cells were transduced with the shRNA vectors shown in a and 24 hours later subjected to puromycin selection for 4 days before gp91 phox expression was analyzed in undifferentiated cells (gray) or in CD11b cells after granulocytic differentiation (>7 days, black bars). Gp91 phox expression was normalized to non-transduced wild type cells (PLB-985). The gp91 phox knock out cell line XCGD-PLB985 served as negative control (n ≥ 3). (d) Plasmid configuration of the gp91 phox KD (LV.sh88/91.Cer), and respective controlvector (LV.Cer) used in this study. (e) Quantitative RT-PCR was performed on single cell clones derived from KD-vector transduced PLB-985 cells to assess gp91 phox knock down efficiency at the mRNA level. Clones were grouped according to vector copy number (VCN) as determined by qPCR (VCN 1: 1.1 ± 0.1, n = 6; VCN 2: 1.7 ± 0.1, n = 3). Expression was normalized to gp91 phox mRNA expression levels of non-transduced PLB-985 cells and cDNA derived from XCGD-PLB985 served as negative control. (f) Schematic structure of the internal cassette used to reconstitute gp91 expression (LV.gp91s. Crim)) in knock down cells and the respective control vector (LV.Crim). cPPT, central polypurine tract; endog., endogenous sequence; hPGK, human phosphoglycerate kinase promoter; IRES, internal ribosome entry site; LTR, self-inactivating long terminal repeat; RRE, rev-responsive element; SFFV, spleen focus forming virus promoter; wPRE, woodchuck hepatitis virus posttranscriptional regulating element. Figure 1f ). After transduction and granulocytic differentiation four distinct populations could be distinguished by FACS analysis (Figure 2a) . Cerulean-positive cells (upper left quadril in Figure 2a ) identified a population of CD11b + PLB-985 cells lacking gp91 phox expression (KD-cells), while non-transduced (ntd) cells were identified by the lack of fluorescence marker expression (lower left quadril). Gp91s expressing cells were visualized by E2-Crimson expression (lower right quadril) while double transduced cells with knock down of endogenous gp91 phox and re-expression of gp91s were identified by the combination of Cerulean and E2-Crimson fluorescence (upper right quadril in Figure 2a ). Although PLB-985 can be efficiently transduced with these vectors according to marker expression (>90%, data not shown), moderate transduction rates (<50%) combined with FACS sorting were preferred to control for low vector copy number. After FACS sorting of the individual cell populations, expression of gp91 phox was reanalyzed by FACS and western blotting (Figure 2b, (Figure 2c ). Next, we stimulated the cells with phorbol-12-myristate-13-acetate (PMA) to test for oxidase activity in KD-and LV.gp91s.Crim double transduced PLB-985 cells. NADPH oxidase activity was assessed by superoxide production over time using the cytochrome C reduction assay. 21 Only residual oxidase activity (0.16 nmol superoxide/minute × 10 6 cells) was detected in KD cells, closely matching the values observed in XCGD-PLB985 control cells thereby reflecting the X-CGD phenotype. As expected from the expression data, LV.gp91s.Crim restored superoxide production in KD cells to wild type levels (2.36 versus 2.33 nmol superoxide/minute × 10 6 cells, respectively; Figure 2d ). Therefore, the X-CGD phenotype can be efficiently mimicked by introducing the LV.sh88/91.Cer vector into wild type PLB-985 cells as estimated by biochemical and functional assays. Functionality can be restored in these cells after transduction with LV.gp91s.Crim.
Knock down approach mimics functional the X-CGD phenotype in CD34 + derived human cells We used granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood from healthy donors to establish a surrogate model for primary human X-CGD cells. Thus, we first analyzed whether the introduction of the knock down vector in CD34 + cells reduces or even abrogates ROS production in their in vitro differentiated myeloid progeny (CD11b documented by a dark blue deposit on the cells (Figure 3a) . This observation was further confirmed by the quantitative cytochrome C assay, in which only residual superoxide production (12.7% of wt) could be measured in the CD11b + KD-cells (Figure 3b ,c) roughly mimicking the complete absence of superoxide production we had observed previously in XCGD-CD34 + derived cells. 18, 22 We also used the dihydrorhodamine123 (DHR123) assay to detect ROS produced by KD-, X-CGD and normal phagocytes after PMA stimulation. Cerulean expressing cells showed only residual rhodamine123 (Rho123) staining suggesting minimal superoxide production by these cells, similar to samples derived from X-CGD patients (Figure 3d) . Thus, the LV.sh88/91.Cer vector efficiently induced the X-CGD phenotype in primary CD34 + cells proving the applicability of our knock down strategy to generate a surrogate human model of X-CGD. , which is not recognized by the shRNA, we reconstituted gp91 phox expression and NADPH-oxidase function in these cells. In our study we used two lentiviral vectors each co-expressing a distinct fluorophore to label cells transduced with the shRNA and/ or the gp91s re-expression vector. This approach facilitate the tracing of untransduced, single or double transduced populations by FACS or fluorescence microscopy and therefore allows for the monitoring of essential controls within the mixed cell population of transduced and untransduced cells. Thus, we normalized the degree of gp91 phox downregulation to the levels of gp91 phox expression in the untransduced fraction of cells in the same experiment. Similarly, doubletransduced cells expressing both, the shRNA and gp91s, were identified by the combination of both fluorochromes. Using this strategy we could compare the expression levels of gp91s to the endogenous gp91 phox levels in one single FACS analysis as represented in Figure 4a middle panel. The alternative approach, which is to integrate shRNA and gp91s in one vector backbone, would not allow for the analysis of the individual populations separately nor for preclinical vector testing and therefore was not considered for our studies. The high and sustained knock down of gp91 phox expression by LV.sh88/91.Cer vector in CD34 + derived cells (>95% depletion of gp91 phox surface expression) allowed us to test a clinical vector lacking a reporter marker for the identification of transduced cells. Gp91s expression levels from the ChimGp91 vector were lower than wild type levels but still within the therapeutic range as demonstrated previously by us in a series of functional analysis. 23 Our system bypasses the lack of patient derived X-CGD CD34 + cells and is also of potential interest for researchers investigating the basic biology of gp91 phox and NADPH-oxidase function. Our knockdown strategy in CD34 + cells may also provide insights into the role of gp91 phox in stem cell physiology, as primary cells lacking gp91 phox seem to be actively cycling (data not shown). The consequences of this observation need to be analyzed in detail but may explain at least in part the lack of long-term engraftment observed in gene therapy trials for XCGD and also may addressed safety issues as a series of cell cycle regulators may be active in gp91 phox -deficient primary cells which could serve as target for vector integration. Consequently integrome analysis of transduced and engrafted gp91 phox -deficient CD34 + cells could provide information on the potential genotoxic effects associated with the use of integrating vectors in CGD. 10 For all these reasons, we believe that disease-specific tools are fundamental to predict the outcome of gene transfer into primary cells. This may be specific for CGD, but it would be worthwhile to implement similar knock-down strategy for other diseases for which primary material is not routinely available.
As an alternative to our approach, induced pluripotent stem cells (iPSCs) have been derived from a large number of normal and defective somatic tissues and have been used to gain insight into the molecular basis of diseases, for testing therapeutic approaches and for drug screenings. Human X-CGD iPSCs have been generated from mesenchymal stem cells derived from bone marrow aspirate of a patient and have been used to correct the disease by Zn-finger nuclease mediated targeting of a gp91 phox transgene into the AAVS1 gene locus. 24 However, transplantable HSCs derived from iPSCs would be the desired cell type for the ex vivo testing of gene therapy vectors and optimization of transduction protocols. Although several reports have described the induction of hematopoietic progenitors from human iPSCs or human embryonal stem cells, the generation of hematopoietic cells with long-term and multilineage engraftment potential has not yet been achieved. [25] [26] [27] [28] [29] [30] [31] [32] In contrast to the sophisticated protocols used for the generation of iPSCs and the subsequent derivation of hematopoietic cells, our shRNA approach could theoretically be performed as a one-step procedure, as both vectors can be mixed before transduction of CD34 + cells generating a surrogate transplantable disease model within 2-3 days while using the same cell source as in clinical gene therapy protocols. Although shRNA-mediated disruption of gene function has been broadly evaluated for therapeutic applications (as reviewed elsewhere), 33 disease modeling of a monogenetic disorder by RNAinterference and subsequent rescue has been only demonstrated for Fanconi anemia using human embryonal stem cells (hESC). 34 However, in this case, overexpression of the therapeutic gene was used to overcome siRNA-mediated downregulation. Hence, we provide the first disease modeling in CD34 + cells by shRNA that in addition can be rescued by delivering a synthetic sequence of the targeted gene. This concept is promising for other rare monogenetic diseases in focus of gene therapy, since codon-optimized transgenes are widely used in current gene therapy approaches and their evaluation is usually hampered by low availability of patient derived samples. 9, [35] [36] [37] Recent progress in designer nuclease approaches, such as zinc-finger and TALE nucleases as well as more recent the CRISPR/Cas9 system, offer the possibility of a true genetic knock out. However, their wide application is still hampered by low efficiency of gene disruption and delivery of the nucleases into CD34 + cells. 22, 38, 39 In conclusion, we provide a straight forward approach to overcome the paucity of X-CGD CD34 + cells by using a lentiviral mediated gp91 phox knock down vector that efficiently abrogates gp91 phox expression as well as NADPH oxidase activity in the myeloid progeny. This surrogate primary X-CGD model enables the evaluation of novel vectors for X-CGD gene therapy in terms of transduction efficiency of CD34 + cells, gp91 phox expression levels and oxidase activity in order to ultimately estimate if a therapeutic benefit can be anticipated upon clinical application of the vector tested. Furthermore, the simplicity of this approach allows its implementation in nearly every laboratory working with lentiviral vectors and with access to primary CD34 + cells. Lastly, the potential applicability of our test system extends beyond gene therapy as it is an ideal model to shed further light on the role of gp91 phox , NADPH oxidases and ROS-production in hematopoietic stem cell biology.
MATeRIAlS AND MeTHODS

Lentiviral vectors and vector production
Commercially available lentiviral transfer plasmids (pLKO.1) harboring shRNAs #64588-#64592 (Sigma-Aldrich, Steinheim, Germany) were used for initial experiments and served for further downstream cloning. The Cerulean sequence was excised from pLeGO-Cer (Addgene plasmid #27351) using the restriction sites for BamHI and EcoRI, blunted and inserted in pCR2.1-TOPO (Life Technologies, Karlsruhe, Germany) to obtain flanking BamHI and NsiI sites to cut and insert it into BamHI and NsiI digested pLKO.1 plasmid replacing the puromycin resistance gene. The thereby obtained pLKO.sh88.PGK. cer was subsequently subjected to NdeI and EcoRI digestion followed by religation and resulting in pLKO.PGK.cer (LV.Cer).
Following manufacturer's protocol, shRNA91 obtained by annealing of two oligonucleotides (sense: 5′-GATCTCCGGCCTATGACTTGGAAA TGGATACTCGAGTATCCATTTCCAAGTCATAGGTTTA-3′, antisense: 5′-AGCTTC AAAAACCTATGACTTGAAAATGGATACTCGAGTATCCATTTCCAAGTCATAGGCC GG-3′) was cloned into the pSupervector (OligoEngine, Seattle, WA) harboring the H1 promoter using BglII and HindIII. The H1-shRNA91 cassette was then excised by EcoRI and KpnI digested, blunted and cloned into the BbsI restriction site within the 3′LTR of pLKO.sh88.PGK.cer resulting in the final KD-vector (LV.sh88/91.Cer) plasmid.
E2-Crimson from the pE2-Crimson plasmid (Clontech Takara Bio, SaintGermain-en Laye, France) was inserted into pHR' .SFFV.IRES.GFP.wPRE 40 by the use of NcoI and SpeI sites in both plasmids, resulting in the gp91control vector pHR' .SFFV.IRES.E2Crimson.wPRE (LV.Crim). The codon-optimized gp91 phox cDNA (gp91s) was PCR amplified from the original PCRscript-gp91s plasmid obtained from GeneArt (Life Technologies) 20 inserting flanking SacII restriction sites (forward primer: 5′-CCGCGGATCCGACCGATCCTGCCACCATG-3′; Figure 4 Knock down, re-expression of gp91 phox and functional rescue of gp91 phox activity in CD34 + HSC derived cells. (a) Mobilized peripheral blood CD34 + cells were transduced with the indicated vectors or vector combination further expanded for 6 days and subsequently subjected to granulocytic differentiation (2-3 weeks). The same gating strategy as described in Figure 2a Error bars = SD, *P < 0.05, **P < 0.01, ***P < 0.001. 
Cell lines and culture conditions
The human PLB-985 myelomonocytic leukemic cell line and its derivative XCGD-PLB985 (XCGD-PLB), in which the CYBB gene encoding for gp91 phox was disrupted by homologous recombination 11 were grown in RPMI 1640 (Gibco/ Life Technologies) complemented with 10% heat-inactivated fetal calf serum (FCS; PAN-Biotech, Aidenbach, Germany), 4 mmol/l L-glutamine and antibiotics (100 U/ml penicillin and 100 μg/μl streptomycin; all from Gibco) in the presence or absence of 4 µg/ml puromycin. HEK293T cells (ATCC) were cultured in Dulbecco's modified Eagle's medium (Gibco) with identical supplements as stated above. PLB-985, XCGD PLB-985 and derivatives were cultured at a density of 2 × 10 5 cells/ml in RPMI 1640 supplemented with 2.5 % heat inactivated FCS, 4 mmol/l L-glutamine, 100 U/ml penicillin, 100 μg/μl streptomycin and 1.25% dimethyl sulfoxide (SigmaAldrich) for at least 7 days to induce granulocytic differentiation. Expression of the marker gene CD11b was used to verify differentiation status (flow cytometry).
Isolation, culture, and transduction of human CD34 + cells
Human CD34-positive cells from G-CSF mobilized peripheral blood of healthy donors were freshly purified using the human CD34 Microbead Kit (MiltenyiBiotec GmbH) according to manufacturer's instructions. For expansion cells were cultured in StemSpanSFEM (StemCell Technologies), 1% penicillin-streptomycin, hSCF (50 ng/ml), hTPO (10 ng/ml), hIGFBP2 (100 ng/ ml) and hFLT3L (50 ng/ml). 41 Following overnight pre-stimulation cells were lentivirally transduced at a mulitplicity of infection of 20-50 with the vector input not exceeding 20% of the total cell culture volume. Therefore, cells were plated at a density of 1 × 10 6 cells per ml in 96-to 24-well-plate format. Half medium exchange was performed after overnight incubation, and in some cases a second round of transduction was performed to introduce the re-expression vector. Cells were further expanded under the same cytokine conditions for 3 days before granulocytic differentiation was initiated by adding 50 ng/ml hG-CSF to the media. To obtain terminally differentiated granulocytes the cells were thoroughly washed with PBS and cultured in IMDM (Lonza) supplemented with 20% heat-inactivated FCS, 4 mmol/l L-glutamine and antibiotics (1% penicillin-streptomycin) in the presence of 50 ng/ml hG-CSF for 2-3 weeks. All cytokines were purchased from Peprotech (Hamburg, Germany). The local Ethics Review Board of the University of Frankfurt Medical School approved the use of these cells and informed consent was obtained in accordance with the Declaration of Helsinki. Quantitative reverse transcription PCR Total RNA was extracted from 10 6 transduced PLB-985 clonal populations using the RNAqueous-Micro Kit with subsequent DNAase treatment (Ambion, Darmstadt, Germany) according to the manual. Next, 1 µg of RNA was subjected to reverse transcription with random primers applying the RETROscript Kit (Ambion) following manufacturer's instructions. Thereby generated cDNA (2.5 µl) was analyzed by quantitative reverse transcription PCR (qRT-PCR) using the LightCycler480 SYBR Green MasterMix following standard procedures on a LightCycler480 device (Roche, Mannheim, Germany). Quantification was facilitated by a standard curve using cDNA of nontransduced PLB-985 cells. GAPDH served as reference gene. Primer were as follows: Gp91 for: 5′-GGTTTTGGCGATCTCAACAGAA-3′; Gp91 rev: 5′-TTCAAAATGGAAGTGGGACAATACA-3′; GAPDH for: 5′-TCGACAGTCAGCCG CATCTTCTTT-3′; GAPDH rev: 5′-ACCAAATCCGTTGACTCCGACCTT-3′.
Determination of viral vector copy number by real-time quantitative PCR Genomic DNA from PLB-985 clonal populations was isolated using the DNeasy Blood & Tissue Kit (Qiagen GmbH, Hilden, Germany). Real-time quantitative PCR to determine VCN was performed using a Roche LightCycler 480 (Roche) applying advanced quantification (LightCycler 480 Software 1.5.0, Roche) with a reference sample known to harbor one single vector integrant in serial dilution (human XCGD PLB-985 clone) as described before. 42 
Western blotting
After differentiation transduced and sorted PLB-985 and control cells washed with ice cold PBS and subsequently lysed in 100 µl lysis buffer buffer (1% (v/v) Triton X-100, 150 mmol/l NaCl, 50 mmol/l Tris-HCl, Ph 7.4, 2 mmol/l EDTA). Protein concentrations were quantified by a standard Bradford assay. Equal amounts of protein per sample (30 μg) were run on 8% SDS polyacrylamide gels and electroblotted onto PVDF membranes that had been blocked using 4% milk powder in PBS-T. Membranes were incubated overnight at 4 °C with primary antibodies (mouse α-human gp91 phox MoAB48, 1:500; rabbit α-actin, Santa Cruz), and peroxidase-conjugated secondary antibodies were used for detection (goat α-mouse/rabbit HRP, Santa Cruz, 1:5,000, 60 minutes, RT) in combination with the ECL detection kit Supersignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL).
Cytochrome C reduction assay Differentiated cell populations were subjected to analysis as described before 21 using a Spectra MAX 340 reader (Molecular Devices, Sunnyvale, CA) and the SOFTmax Version 2.02 PRO software. The mean absorbance values of duplicates at 550 nm were converted based on the extinction coefficient of cytochrome c: ΔE 550 = 21 × 10 3 mol/l −1 cm −1
. All chemicals were purchased from Sigma-Aldrich.
NBT assay
Granulocytes obtained after in vitro differentiation were sorted by FACS to obtain a pure population, of KD-vector expressing cells. Cells were subsequently pelleted and resuspended in prewarmed PBS supplemented with 1 mg/ml NBT and 2 µg/ml PMA (both Sigma-Aldrich). After 30 minutes at 37 °C cells were transferred on glass slides and photos were taken using a Nikon Eclipse TE300/DS-U1.
DHR assay
The DHR assays were performed as described previously. 43 Briefly, washed samples were subjected to surface marker staining in HBSS (Gibco) supplemented with 7.5 mmol/l D-Glucose, 0.5% BSA, 2,000 U/ml Catalase (C3155) and 5 µg/ml DHR123 at 37 °C. Following incubation at 37 °C for 10 minutes PMA was added to a final concentration of 0.1 µg/ml. Samples were further incubated for 15-20 minutes at 37 °C under agitation, the reaction was stopped on ice and the fluorescence signals were recorded using BD FACS Canto II, immediately. All chemicals were purchased from Sigma-Aldrich.
Animals and transplantation NSG mice (NOD.Cg-Prkdc scid
Il2rg tm1Wjl
/SzJ) were obtained from Jackson Laboratories (Bar Harbor, ME). Animal experiments were approved by the regional council (Regierungspräsidium, Darmstadt, Germany) and conducted in compliance with the local animal experimentation guidelines. Two days post last transduction transduced human CD34 + cells were washed twice, resuspended in X-VIVO 10 medium (Lonza) and 10 6 cells were injected intravenously into sublethally irradiated (2.4 Gy) 8-9 week-old NSG mice. Mice were sacrificed 8 weeks later to isolate bone marrow that was then subjected to erythrocyte lysis (BD Pharm Lysis, BD Biosciences) and analysis (flow cytometry). Transplanted mice were kept in individually ventilated cages and drinking water was supplemented with 1.6 g/l neomycin for 2 weeks.
Statistical analysis
Statistical significance was calculated by unpaired or paired two-tailed t tests according to experimental design. Bar diagrams show mean + SD. *P < 0.05, **P < 0.01, ***P < 0.001.
